Synthesis and cytotoxic activity of novel 10-alkylated docetaxel analogs

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 5, 1998, Pages 427-432

  Nakayama, Kiyoshi ^a   Terasawa, Hirofumi ^a   Mitsui, Ikuo ^a   Ohsuki, Satoru ^a   Uoto, Kouichi ^a   Iimura, Shin ^a   Soga, Tsunehiko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL;

ALKYLATION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ALKYLATION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; MODELS, MOLECULAR; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0032478246     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00040-7     Document Type: Article

References (21)

1. 1. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. J. Am. Chem. Soc. 1971, 93, 2325.
2. 2. Gueritte-Voegelein, F.; Guenard, D.; Lavelle, F.; Le Goff, M. -T.; Mangatal, L.; Potier, P. J. Med. Chem. 1991, 34, 992.
3. 3. In Taxol: Science and Applications; Suffness, M., Ed.; CRC: Boca Raton, FL, 1995; pp 209-235.
4. 4. In Taxane Anticancer Agents: Basic Science and Current Status; Georg, G. I.; Chen, T. T.; Ojima, I., Vyas, D. M.; Ed.; ACS Symposium Series 583; American Chemical Society: Washington, DC, 1995; pp 31-57.
5. 5. (a) Schiff, P. B.; Fant, J.; Horwitz, S. B. Nature 1979, 277, 665.
6. (b) Schiff, P. B.; Horwitz, S. B. Proc. Natl. Acad. Sci. 1980, 77, 1561.
7. 6. (a) Dorr, R. T. Ann. Pharmacother., 1994, 28, S11.
8. (b) Slichenmyer, W. J.; Hoff, D. D. V. J. Clin. Pharmacol., 1990, 30, 770.
9. (c) Rose, W. C.; Clark, J. L.; Lee, F. Y. F.; Casazza, A. M. Cancer Chemother. Pharmacol., 1997, 39, 486.
10. 7. (a) Deutsh, H. M.; Glinski, J. A.; Hernandez, M.; Haugwitz, R. D.; Narayanan, V. L.; Suffness, M.; Zalkow, L. H. J. Med. Chem., 1989, 32, 788.
11. (b) Mathew, A. E.; Mejillano, M. R.; Nath, J. P.; Himes, R. H.; Stella V. J. J. Med. Chem., 1992, 35, 145.
12. (c) Greenwald, R. B.; Pendri, A.; Bolikal, D. J. Org. Chem., 1995, 60, 331.
13. (d) Golik, J.; Wong, H. S. L.; Chen, S. H.; Doyle, T. W.; Wright, J. J. K.,; Knipe, J.; Rose, W. C.; Casazza, A. M.; Vyas, D. M. Bioorg. Med. Chem. Lett., 1996, 6, 1837.
14. (e) Bourzat, J. D.; Commercon, A. PCT Patent Appl., WO 9323389-A1, 1993.
15. 8. Chaudhary, A. G.; Kingston, D. G. I. Tetrahedron Lett., 1993, 34, 4921.
16. 9. Giese, B. Angew. Chem. Int. Ed. Engl., 1985, 24, 553, and references cited therein.
17. 13 minimization option of the Quanta program (method: adopted basis Newton-Raphson; energy gradient tolerance: 0.001 Kcal/mol Å).
18. 11. (a) Commercon, A.; Benzard, D.; Bernard, F., Bourzat, J. D. Tetrahedron Lett., 1992, 33, 5185.
19. (b) Didier, E.; Fouque, E.; Taillepied, I.; Commercon, A. Tetrahedron Lett. 1994, 35, 2349.
20. 12. Gueritte-Voegelein, F.; Guenard, D.; Mangatal, L.; Potier, P.; Guilhem, J.; Cesario, M.; Pascard, C. Acta crystallogr. 1990, C46, 781.
21. 14. The water-solubility data for 10-alkylated docetaxel analogs will be reported in detail in the near future.